

**RESPONSE OF EGYPTIAN CHILDREN
TO HEPATITIS B VACCINE**

THESIS

Submitted for Fulfillment of
Ph.D. in childhood studies
"Medical Department"



By

Rasha Ahmed El Hossary

Under Supervision Of

Prof. Dr. Yehia Mohamed El Shazly
Prof. of general medicine, Faculty of
medicine -Ain Shams University

Dr. Aisha Yassin Abdel Ghaffar
Ass. prof. of clinical pathology
Faculty of medicine-Ain Shams University

Dr. Khaled Hussien Taman
Lecturer of Pediatrics
Institute post graduate of childhood
Studies - Ain Shams University
Ain Shams University

1996





ACKNOWLEDGMENT

I am extremely grateful to **Professor Dr. El Shazely Y.M.** , professor of general medicine ,Faculty of Medicine, Ain Shams University, for his generous supervision and helpful advice which made me accomplish this work in its present form . Working under his supervision has been a source of constant delight and indeed a great privilege .

I wish to express my sincere gratitude to **Dr. Aisha Y.A Ghaffar** Assistant Prof. of Clinical Pathology, Faculty of Medicine, Ain Shams University , for her honest supervision, kind assistance, the great effort she did and the time she devoted to help me in this work .

I feel deeply thankful to **Dr. Taman, K.H.** ,Lecturer of paediatrics, Institute of Post graduate childhood Studies, Ain Shams University, for his great guidance and keen advice that were of great importance .

CONTENTS

	Page
List of Abbreviation .	5
List of Figures .	6
List of Tables.	7
Introduction And Aim Of Work	8
Review Of Literature	
• The hepatitis viruses.	9
• Multitransfused Patients.	10
• The Hepatitis B virus.	13
• The structure and genetic organization of HBV.	15
• Biophysical properties of HBV	17
• Modes of transmission of HBV infection.	
Perinatal transmission.	25
• The immune response in HBV infection.	28
• Sequence of HB markers in cases with HBV infection.	31
• The delta agent.	43
• Vaccination against HBV infection.	48
• Side effects of HB vaccine.	51
• Who should be vaccinated.	52
• Prescreening and Testing for immunity to HB infection.	57
• Dosage and Different schedules of vaccination.	58
• Is HBvaccination protective against HBV infection.	68
• How long does protection last.	69
• Combined Hepatitis B vaccine formulas.	71
• Hepatitis B vaccination in children with schistosoma mansoni .	73
• Prevention of perinatal transmission of HBV.	74
• Vaccination of children in special circumstances.	77

• Non A non B viral hepatitis .	81
Subjects And Methods.	84
Results.	90
Discussion.	111
Summary And Conclusion.	122
Recommendation.	124
References.	125
Arabic Summary.	155

List of Abbreviation


ACIP	Advisory committee on Immunization Practice
AIDS	Acquired Immune Deficiency Syndrome .
Anti HBsAb	Anti Hepatitis B surface antibody .
Anti HBcAb	Anti Hepatitis B core antibody .
HBsAg	Hepatitis B surface antigen .
HBeAg	Hepatitis B e antigen .
HBV	Hepatitis B Virus .
HCV	Hepatitis C Virus .
IgG	Immuno globulin G .
IgM	Immuno globulin M .
MSD	Merck Sharp & Dohme .
ORF	Opening Reading Frams .
NS4	The fourth non structural gene region .
PHSA	Polymerized Human Serum Albumin .
PCR	polymerase chain reaction .
SKF	Smith Kline and French Beckman Co.
WHO	World Health Organization .

List of Figures

	Page
Fig (1) : Hepatitis B Virus .	17
Fig (2) : Hepatitis B virus structure .	18
Fig (3) : Serological events during acute HBV infection .	34
Fig (4) : Serological events in carrier state .	35
Fig (5) : Immune response three doses of HB vaccine .	61
Fig (6) : Decrease in anti Hbs titres in immunized subjects .	62
Dig (1) : HBsAb before vaccination .	106
Dig (2) : HBsAb before the third dose of vaccine .	107
Dig (3) : HBsAb after the third dose of vaccine .	108
Dig (4) : HBsAb one year after the third dose of vaccine .	109
Dig (5) : Sex distribution .	110

List of Tables

	Page
Table (I) : Serological pattern in hepatitis B infection .	18
Table (I) : Collective data of HB markers in first occasion .	95
Table (II) : Collective data of HB markers in 2nd occasion .	96
Table (III) : Collective data of HB markers in 3rd. occasion.	97
Table (IV) : Collective data of HB markers in 4th. occasion	98
Table (V) : Infection rate and the effect of HB vaccine .	99
Table (VI) : Comparative study of surface antigen in 1st. and 2nd. occasion .	100
Table (VII) : A comparative study between surface antigen in 1st. and 3rd. occasion .	100
Table (VIII) : A comparative study between core antibody in 1st. and 2nd. occasion.	101
Table (IX) : A comparative study between core antibody in 1st. and 3rd. occasion .	101
Table (X) : A comparative study of qualitative assay of surface antibody in 1st. and 2nd. occasion.	102
Table (XI) : A comparative study of qualitative assay of surface antibody in 1st. and 3rd. occasion .	102
Table (XII) : A comparative quantitative assay of surface antibody in 2nd , 3rd. and 4th. occasion .	103
Table (XIII) : Sex comparizon between immune M. and immune F.	103
Table (XIV) : A quantitative assay of anti HBs. after complete the course of vaccination .	104
Table (XV) : Side effects of HB vaccine in our studied group .	105



Introduction and **A**im of **T**he **W**ork

